The Chief Executive Officer of the Saudi Food and Drug Authority (SFDA), H.E. Dr. Hisham S. Aljadhey, headed the Kingdom of Saudi Arabia’s delegation at the Annual Meeting of the International Society of Pharmacovigilance (ISoP) from October 1 to 5, 2024. The SFDA’s participation in the Meeting, held in Montreal, Canada, aligns with its fruitful efforts to collaborate with the international community and enhance global drug safety efforts.   Dr. Aljadhey highlighted the transformative impact of digital technologies on pharmacovigilance worldwide during his participation in the panel discussion titled “Current Status of Pharmacovigilance in the Digital Era Around the World.” Speakers from Health Canada, the U.S. Food and Drug Administration (FDA), the World Health Organization (WHO), and the European Medicines Agency (EMA), along with officials from other significant international authorities, participated in the discussion.   “The SFDA initiatives are pioneering advancements in digital pharmacovigilance,” Dr. Aljadhey stated, “It has taken the lead in incubating digital technologies into drug safety, with key projects including the ‘Vigilance’ electronic system for managing adverse drug reactions (ADRs), the Risk Minimization Measures (aRMMs) e-learning platform, and other advanced technology projects that showcase the Kingdom's scientific excellence.“   “As we enter a new era in pharmacovigilance, technology is revolutionizing the monitoring and understanding of drug safety. Advanced technologies, such as artificial intelligence (AI), machine learning (ML), and natural language processing (NLP), are empowering regulators and healthcare providers to detect safety signals more efficiently, respond to adverse events more promptly, and make science-based decisions to protect public health.”   “While digital technologies offer immense potential, they also present challenges such as data privacy concerns, managing large volumes of data, integrating diverse data sources, and ensuring data quality. Addressing these challenges requires proactive regulatory engagement by fostering collaboration between regulators, pharmaceutical companies, and technology providers,” Dr. Aljadhey added.   On the sidelines of the ISoP Annual Meeting, Dr. Aljadhey met with senior officials from Health Canada. Further, Dr. Aljadhey met with several leading Canadian companies in biotechnology, biopharmaceuticals, vaccines, and biological materials to explore collaboration opportunities in research, knowledge exchange, and capacity building.   At the research exhibition accompanying the ISoP Meeting, the SFDA team reviewed ten scientific papers in the field of pharmacovigilance.   The ISoP, which consists of around 1,000 members from 108 countries, aims to provide an international forum for all those interested in the clinical and scientific aspects of drug safety.